Back to Authors

Schuetz, Audrey N

0000-0002-5837-270X

Mayo Clinic

Mayo Clinic

Citations 25

Phenotypic and Genomic Profiling of Staphylococcus argenteus in Canada and the United States and Recommendations for Clinical Result Reporting
Bommersbach, Carl E., Zittermann, Sandra , Burnham, Carey‐Ann D. , Patel, Robin , Schuetz, Audrey N. , Patel, Samir N. , Kus, Julianne V. , Bommersbach, Carl, Burnham, C A , Patel, Robin , Schuetz, Audrey N , Kus, Julianne V , Eshaghi, Alireza

Journal of Clinical Microbiology | March 16, 2021 | Volume: 59 | Issue: 6 | Pages: No page available

10.1128/jcm.02470-20 Get It

Staphylococcus argenteus is a newly described species, formerly known as S. aureus clonal complex 75 (CC75). Here, we describe the largest collection of S. argenteus isolates in North America, highlighting identification challenges.
All You Need to Know and More about the Diagnosis and Management of Rare Mold Infections
Hoenigl, Martin , Schuetz, Audrey N. , Zhang, Sean X. , Cornely, Oliver A. , Schuetz, Audrey N , Zhang, Sean X , Cornely, Oliver A , Hoenigl, Martin , Levitz, Stuart M.

mBio | February 22, 2021 | Volume: 12 | Issue: 1 | Pages: No page available

10.1128/mbio.02920-20 Get It

Invasive mold infections caused by molds other than Aspergillus spp. or Mucorales are emerging. The reported prevalences of infection due to these rare fungal pathogens vary among geographic regions, driven by differences in climatic conditions, susceptible hosts, and diagnostic capabilities.
When Should Asymptomatic Persons Be Tested for COVID-19?
Schuetz, Audrey N. , Mehta, Ninad , Campbell, Sheldon , Mitchell, Stephanie L. , Palavecino, Elizabeth , Butler‐Wu, Susan M. , Mehta, Ninad , Mitchell, Stephanie , Butler-Wu, Susan , Schuetz, Audrey N , Hemarajata, Peera , Miller, Melissa B.

Journal of Clinical Microbiology | October 7, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.02563-20 Get It

On 24 August 2020, the Centers for Disease Control and Prevention (CDC) updated its website to highlight that asymptomatic individuals, even those with exposure to a COVID-19-positive contact, do not necessarily need to be tested unless they have medical conditions associated with increased risk of severe illness from COVID-19. The CDC subsequently updated its guidance on 19 September 2020 to support testing of asymptomatic persons, including close contacts of persons with documented SARS-CoV-2 infection.
Application, Verification, and Implementation of SARS-CoV-2 Serologic Assays with Emergency Use Authorization
Theel, Elitza S. , Couturier, Marc Roger , Filkins, Laura , Palavecino, Elizabeth , Mitchell, Stephanie L. , Campbell, Sheldon , Pentella, Michael , Butler‐Wu, Susan M. , Jerke, Kurt, Dharmarha, Vaishali, McNult, Peggy, Mitchell, Stephanie , Butler-Wu, Susan , Schuetz, Audrey N , Schuetz, Audrey N.

Journal of Clinical Microbiology | October 6, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.02148-20 Get It

Interest continues to grow regarding the role of serologic assays for the detection of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) status to many SARS-CoV-2 serologic assays. In this document, expert recommendations from clinical microbiologist members of the American Society for Microbiology (ASM) concerning detailed verification strategies for SARS-CoV-2 serologic assays with FDA EUA are provided, as are insights into assay limitations and reporting considerations for laboratories.
Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli
Albano, Mariana , Karau, Melissa J. , Schuetz, Audrey N. , Patel, Robin , Patel, Robin , Schuetz, Audrey N

Journal of Clinical Microbiology | September 22, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.00966-20 Get It

Cefiderocol (CFDC) is a siderophore cephalosporin with activity against Gram-negative bacterial species that are resistant to carbapenems and other drugs. The MICs of CFDC were determined for 610 Gram-negative bacilli, including 302 multinational Enterobacterales isolates with characterized mechanisms of beta-lactam resistance, 180 clinical isolates from the Mayo Clinic and Mayo Clinic Laboratories not characterized for specific resistance mechanisms, and 128 isolates with CFDC MICs of ≥8 μg/ml obtained from International Health Management Associates, Inc.